Summary
Synopsys Inc. reported its first quarter fiscal 2016 financial results on February 22, 2016, for the period ending January 30, 2016. The company demonstrated a 5% increase in total revenue, reaching $568.6 million, primarily driven by growth in time-based license revenue, a key component of its recurring revenue model. Despite a revenue increase, net income saw a slight decrease of 8% to $60.0 million, attributed to higher operating expenses, particularly in research and development and sales and marketing, influenced by headcount growth from recent acquisitions. The company's balance sheet shows a decrease in cash, cash equivalents, and short-term investments by 27% to $705.9 million, largely due to significant stock repurchases and cash used for acquisitions. Synopsys maintained compliance with its debt covenants and expressed confidence in its liquidity to meet future obligations. Investors should note the continued strategic focus on expanding IP offerings and the software quality and security market through acquisitions, while managing operational costs and leveraging its stable time-based revenue model.
Financial Highlights
53 data points| Revenue | $568.60M |
| Cost of Revenue | $129.44M |
| Gross Profit | $439.16M |
| R&D Expenses | $196.71M |
| Operating Expenses | $368.05M |
| Operating Income | $71.11M |
| Interest Expense | $673K |
| Net Income | $60.03M |
| EPS (Basic) | $0.39 |
| EPS (Diluted) | $0.39 |
| Shares Outstanding (Basic) | 152.97M |
| Shares Outstanding (Diluted) | 155.28M |
Key Highlights
- 1Total revenue increased by 5% to $568.6 million for the first quarter of fiscal 2016 compared to the prior year.
- 2Time-based license revenue, representing 82% of total revenue, grew by 8% to $464.3 million.
- 3Net income decreased by 8% to $60.0 million, primarily due to a 6% increase in operating expenses.
- 4Cash, cash equivalents, and short-term investments decreased by 27% to $705.9 million, influenced by substantial stock repurchases and acquisition-related spending.
- 5The company repurchased approximately $180 million of its stock during the quarter through accelerated share repurchase agreements.
- 6Operating expenses increased by 6% to $368.0 million, with R&D and Sales & Marketing seeing significant rises.
- 7Synopsys' effective tax rate decreased to 6.7% from 14.9% in the prior year's comparable period, partly due to the reinstatement of the U.S. federal research tax credit.